INTRODUCTION
============

Worldwide, more than 1 million people develop colorectal cancer (CRC) annually, and the CRC-related mortality rate is almost 33% in developed countries.[@B1] CRC is the second leading cause of cancer-related death in the US, and it has the second highest crude incidence (54.6) per 100000 population in both male and female in Korea, with an incidence that is still increasing.[@B2][@B3]

Research has shown that chronic kidney disease (CKD) is significantly associated with an increased risk of CRC. compared with CRC risk in the general population regardless of comorbidities.[@B4] CKD is prevalent worldwide and has high incidences of 13.1% in the US and 13.7% in Korea among individuals older than 20 years of age.[@B5][@B6] Patients with CKD may progress to end-stage renal disease and develop subsequent complications.[@B7] However, the etiology by which the risk of CRC increases with CKD is still unclear. With respect to the risk of cancer in pre-dialysis CKD, Park, et al.[@B8] reported the incidence rate of all neoplasms in pre-dialysis CKD patients, compared with that in matched controls, using Korean nationwide population-based study: they showed that the incidence of digestive cancer was lower in individuals with pre-dialysis CKD than in matched controls, although they did not provide a reason for the finding.

The leading cause of CKD is diabetes mellitus (DM), which accounts for 44% of new CKD cases.[@B9] Recently, a population-based, cross-sectional study demonstrated a relative risk of CRC of 2.9 in subjects with a history of type II DM.[@B10] Although this phenomenon is similar between male and female, it is more pronounced in individuals with a family history of CRC.[@B11] Insulin and its structural homolog insulin-like growth factor-I are believed to promote colorectal carcinogenesis, although issues including any related risk quantification remain unclear.[@B11][@B12][@B13][@B14] Several studies have reported that CKD and DM each have a significant association with CRC incidence.[@B4][@B11][@B15][@B16][@B17] However, to the best our knowledge, no study has compared the relative CRC risk of patients with both CKD and DM with that of healthy control subjects, CKD only patients, or DM only patients. Thus, in the present study, to determine the effect of CKD with or without DM on the risk of CRC, we investigated the association of CKD, DM, or both diseases with the incidence of CRC. Accordingly, we stratified the study population into four groups of healthy control (CKD−/DM−), DM only (CKD−/DM+), CKD only (CKD+/DM−), and CKD with DM (CKD+/DM+) patients, and investigated the relative risk of CRC among the groups. Additionally, sex differences in the risk of CRC were also examined among these four groups.

MATERIALS AND METHODS
=====================

Data source
-----------

This study was conducted using data from the National Health Insurance Service (NHIS)-Health Examination Cohort in the Republic of Korea. Detailed information concerning this cohort is described in [Supplementary Material 1](#S1){ref-type="supplementary-material"} (only online). In this study, the date of the health examination from 2002 to 2003 was considered the index date (it also indicates the baseline period). This study was approved by the Institutional Review Board of the Ewha Womans University Mokdong Hospital (IRB approved number; 2018-01-006).

Study subject cohort
--------------------

To evaluate the study cohort for further analyses, we excluded subjects from the baseline population of the NHIS--health examination cohort in accordance with the following criteria: having undergone peritoneal dialysis, hemodialysis, or kidney transplantation (n=1733) and having inflammatory bowel disease or familial and hereditary polyposis (n=21056). These subjects were identified through claimed records according to diagnosis and/or medical treatment codes. Subjects with a self-reported previous cancer history (n=2909), those diagnosed with any type of cancer (n=6739), and those who died (n=1611) within 1 year after the index date were also excluded. Additionally, subjects with missing data in terms of smoking status and body mass index (BMI) were excluded (n=18751). Among the subjects remaining after applying the exclusion criteria (n=461996), we formed case and control groups according to the following definitions: prevalent CKD and DM were defined according to claimed records of hospital utilization and drug prescriptions. Prevalent CKD subjects were defined as those who visited an outpatient clinic on at least two different days or those who were hospitalized more than once with a diagnosis code of 'N18', 'N19', 'I12', 'I13', 'E10.2', 'E11.2', 'E13.2', or 'E14.2' based on the International Classification of Diseases, 10th revision, during the baseline period. Prevalent DM subjects were defined as those with at least two records of prescription insulin or oral hypoglycemic agents with a diagnosis code of 'E10--14'.[@B18][@B19] The CRC incidence was defined as the first hospitalization with a diagnosis code of 'C18--20' from 1 year after the index date to December 31, 2013.

To achieve the study objectives, prevalent CKD/DM patients were grouped as patients with DM only (CKD−/DM+, n=17700), with CKD only (CKD+/DM−, n=22643), and with both CKD and DM (CKD+/DM+, n=8506). To construct the control group, two control subjects per one patient were selected through individual matching according to sex, age (±4 years), and health examination month (±3 months) and year (n=97698). The flow diagram of this study is presented in [Supplementary Fig. 1](#S2){ref-type="supplementary-material"} (only online). A description of the clinical and lifestyle variables is provided in [Supplementary Material 2](#S3){ref-type="supplementary-material"} (only online).

Statistical analysis
--------------------

The results are presented as means±standard deviations for numeric variables and as numbers of subjects and percentages for categorical variables. As the endpoint, CRC incidence was defined as the first hospitalization with a diagnosis code of 'C18--20' from 1 year after the index date to December 31, 2013. Follow up was calculated from the index date to the date of the first diagnosis of CRC, death, or end of the study (December 31, 2013). The incidence of CRC was estimated as 100000 person-years. We also used Poisson regression analysis to estimate the incidence rate ratio (IRR) of CRC risk and 95% confidence intervals (CIs) for each patient group in comparison to controls. The Kaplan-Meier method and log-rank test were used to evaluate the difference in the cumulative incidence of CRC between the control subjects and patients with CKD, DM, or both. The hazard ratios (HRs) of CRC in the disease groups (CKD−/DM+, CKD+/DM−, CKD+/DM+) were estimated using the Cox proportional hazards regression model. Its assumption was tested using the Schoenfeld residuals and was satisfied. Using univariate Cox proportional hazards regression analyses, we assessed the individual effects of potential risk factors on CRC risk. Significant (*p*\<0.1) risk factors identified from the univariate analyses \[presence of CKD or DM, age, sex, income, BMI, smoking status, alcohol consumption, exercise, Charlson Comorbidity Index (CCI) score, family history of cancer, metformin use, and aspirin or NSAID use\] were entered into the Cox proportional hazards regression model. The differences in HR among the patient subgroups according to the presence of CKD, DM, or both were also tested using pairwise comparisons in the multivariate Cox proportional hazards regression model. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA), and statistical significance was set as 0.05 in two-sided tests.

RESULTS
=======

Baseline characteristics of the four groups stratified according to the presence of CKD or DM
---------------------------------------------------------------------------------------------

The disease groups consisted of CKD−/DM+ (n=17700), CKD+/DM− (n=22643), and CKD+/DM+ groups (n=8506). After 1:2 matching by age, sex, health examination year and month, the healthy control group consisted of 97698 individuals. The baseline characteristics of the study population are shown in [Table 1](#T1){ref-type="table"}.

CRC incidence according to CKD or DM
------------------------------------

We initially investigated the difference in CRC incidence according to CKD or DM using the Kaplan-Meier method and log-rank test, which showed that the cumulative incidence of CRC was significantly higher in the CKD or DM group, compared with that in the control group (*p*\<0.0001) ([Supplementary Fig. 2](#S4){ref-type="supplementary-material"}, only online). During the median follow-up period of 10.7 years (interquartile range: 10.2--11.2), the incidences of CRC per 100000 person-years were 179.2 (95% CI, 170.9--187.4) in the control group, 223.3 (95% CI, 201.3--245.2) in the CKD−/DM+ group, 234.3 (95% CI, 214.7--253.9) in the CKD+/DM− group, and 285.4 (95% CI, 249.6--321.2) in the CKD+/DM+ group. We also estimated IRR using the Poisson model, and the trends were similar to the incidence of CRC ([Table 2](#T2){ref-type="table"}). These results indicated that the incidence rate of CRC was higher in the disease group than in the control group. When assessed according to sex, similar to the whole population, CRC incidence was higher in the disease group than in the control group for both male and female. However, a difference in the increase in CRC incidence (per 100000 person-years) in the disease groups, compared with the control groups, was observed according to sex: the CRC incidence was 29.8% higher in the CKD+/DM+ group than in the control group (302.5 vs. 212.5, respectively) in male and 47.2% higher in the CKD+/DM+ group than in the control group (264.8 vs. 139.8, respectively) in female.

Impact of CKD or DM on the cumulative incidence of CRC
------------------------------------------------------

To investigate the association between CRC and each variable, we performed Cox proportional hazards regression analyses. An unadjusted Cox analysis showed that CKD and DM were each significantly associated with an increased incidence of CRC, compared with the controls \[HR, 1.26 (95% CI, 1.13--1.40) in CKD−/DM+ group; HR, 1.31 (95% CI, 1.19--1.44) in CKD+/DM− group\]. Furthermore, the HR in the CKD+/DM+ group was 1.61 (95% CI, 1.41--1.84). When all of the variables were adjusted for in the multivariate analysis, CKD, DM, and CKD with DM were each still independently correlated with an increased incidence of CRC, compared with the controls \[HR, 1.34 (95% CI, 1.16--1.55) in CKD−/DM+ group; HR, 1.31 (95% CI, 1.18--1.46) in CKD+/DM− group; and HR, 1.63 (95% CI, 1.37--1.94) in CKD+/DM+ group\] ([Table 3](#T3){ref-type="table"}). In the multivariate Cox proportional hazards regression model, older age (HR, 1.06; 95% CI, 1.06--1.07), male (HR, 1.55; 95% CI, 1.41--1.72), current smoker status (HR, 1.17; 95% CI, 1.06--1.30), frequent alcohol drinking (≥3 times/week) (HR, 1.36; 95% CI, 1.20--1.53), and an increased CCI score (HR, 1.09; 95% CI, 1.04--1.13) were significantly associated with the risk of CRC, whereas the incidence of CRC was significantly decreased in those with a higher income, compared with a lower income (HR, 0.98; 95% CI, 0.97--1.00) ([Table 3](#T3){ref-type="table"}).

Difference in the impact of CKD, DM, or both on CRC incidence between male and female
-------------------------------------------------------------------------------------

To examine whether the impact of CKD, DM, or both on CRC incidence differed between male and female, we performed the Kaplan-Meier method with log-rank test according to sex. Consequently, the cumulative incidence of CRC was significantly increased in the CKD−/DM+, CKD+/DM− and CKD+/DM+ groups, compared with the control group, in both male and female. However, in male, no significant difference in the cumulative incidence of CRC was observed between the CKD−/DM+ and CKD+/DM+ groups or between the CKD+/DM− and CKD+/DM+ groups ([Fig. 1A](#F1){ref-type="fig"}). On the other hand, in female, the cumulative incidence of CRC was significantly higher in the CKD+/DM+ group than in the CKD−/DM+ or CKD+/DMgroup (CKD−/DM+ vs. CKD+/DM+, *p*=0.005, and CKD+/DMvs. CKD+/DM+, *p*=0.003) ([Fig. 1B](#F1){ref-type="fig"}). According to multivariate Cox regression analysis adjusting for all possible variables, CKD, DM, or both was independently associated with an increase in CRC incidence compared, with the controls, in both male and female ([Table 4](#T4){ref-type="table"}). In this model, the adjusted HRs in the CKD−/DM+, CKD+/DM−, and CKD+/DM+ groups were, respectively, 1.32 (*p*=0.002), 1.26 (*p*\<0.001), and 1.43 (*p*=0.002) in male, and 1.38 (*p*=0.010), 1.39 (*p*\<0.001), and 2.00 (*p*\<0.001) in female.

The other independent risk factors associated with the risk of CRC in male (older age, economic income, current smoker status, frequent alcohol drinking, and higher CCI score) were consistent with those in the whole population ([Table 4](#T4){ref-type="table"}). In contrast, in female, economic income and frequent alcohol drinking were not significantly associated with the risk of CRC; however, a lack of exercise (vs. ≥3 times/week) was independently associated with the risk of CRC (HR, 1.27; *p*=0.013) ([Table 4](#T4){ref-type="table"}).

To evaluate the differential impact of CKD, DM, or both on CRC incidence in male and female, adjusted HRs were compared among the disease groups. The HR for CRC incidence was significantly higher in the CKD+/DM+ group than in the CKD−/DM+ or CKD+/DM− groups in the whole population (*p*=0.027 and *p*=0.025, respectively) and in female (*p*=0.007 and *p*=0.018, respectively) after adjusting for all possible variables. However, no statistical difference was observed in the cumulative incidence of CRC between the CKD+/DM+ and CKD−/DM+ or CKD+/DM− groups in male ([Fig. 2](#F2){ref-type="fig"}).

DISCUSSION
==========

The present study indicated that individuals with CKD or DM face a significantly increased risk of CRC, compared with non-diabetic and non-CKD populations, irrespective of sex. However, in female, CRC incidence was significantly higher in CKD+/DM+ individuals than in CKD−/DM+ or CKD+/DM− individuals, which was not observed in male. In addition, the clinical and environmental risk factors associated with the risk of CRC differed between male and female.

Consistent with several previous studies,[@B4][@B11][@B15][@B16][@B17] CKD and DM individually were shown to be positively associated with the incidence of CRC in our study. The increased prevalence of CKD is likely attributable to a progressively aging population and increased prevalences of obesity, diabetes, and hypertension.[@B20] The association between CRC and DM was first suggested in 1932 and has since been confirmed unequivocally in several observational studies.[@B14][@B15][@B16][@B21][@B22][@B23][@B24][@B25][@B26] A recent meta-analysis reported a relationship between diabetes and increased risk of CRC in both female and male.[@B23] A causal association between DM and CRC is biologically reasonable. DM is characterized by high insulin levels that can stimulate cell proliferation via two pathways: a minor and major pathway. These pathways may result in hypersecretion of insulin-like growth factor,[@B11] which plays a pivotal role in colorectal carcinogenesis.[@B11][@B27] Other factors associated with insulin resistance, such as high levels of triglycerides or glucose, have been linked to colorectal carcinogenesis.[@B28] We also found that both DM and CKD were independent risk factors for CRC in our study. CKD was significantly associated with an increased incidence of CRC irrespective of DM. Moreover, the incidence rate of CRC was higher in the CKD+/DM− group than in the CKD−/DM+ group, although the difference was not statistically significant. To date, the risk of CRC in pre-dialytic CKD patients has been examined in a few studies, including a recent study by Wu, et al.[@B4][@B29] Compared with prior studies, the median follow-up period was longer and more study subjects were examined in our study. To investigate the effect of CKD or DM on increased incidence of CRC, we analyzed the data after stratifying the patients according to the presence of CKD or DM (CKD−/DM+, CKD+/DM−, and CKD+/DM+).

Interestingly, multivariate Cox analysis showed that, in female, CRC incidence was significantly higher in the CKD+/DM+ group than in the CKD−/DM+ or CKD+/DM− group. However, in male, the CRC incidence in the CKD+/DM+ group was not different from that in the CKD−/DM+ or CKD+/DM− group. This result suggests a significant sex difference in the effects of CKD and DM on the risk of CRC. This phenomenon can be explained by several reasons. First, the effects of other clinical or environmental factors on the risk of CRC differ between male and female. The incidence of CRC was higher in the male than in the female control subjects (212.5 per 100000 person-years vs. 139.8 per 100000 person-years, respectively), indicating that other factors besides CKD and DM may have a greater impact on CRC risk in male than in female. However, the causes of these results are difficult to completely explain, and further studies are needed.

Our results highlighted sex differences for other clinical and environmental factors associated with the risk of CRC. Lower economic income and frequent alcohol drinking were significant risk factors for CRC in male, but not in female, while the lack of exercise was a risk factor for CRC in female, but not in male. In traditional Korean society and in accordance with Confucian principles, drinking is acceptable for male but not female.[@B30] Although contemporary Korean female drink at a younger age and consume more alcohol, compared with prior generations, the observed sex difference in the rate of alcohol drinking, with higher consumption by male than female, is greater in Korea than in Australia and the US.[@B31] In addition, Fedirko, et al.[@B32] showed a stronger relative risk for moderate drinkers, compared with non-/occasional drinkers, for male than female. In contrast, regular physical activity, either occupational or leisure time, has been shown to be associated with protection from CRC.[@B33] However, according to Kim, et al.,[@B34] the physical activity status, perceived self-efficacy, and benefits of physical activity were significantly lower in Korean female than in Korean male. Thus, frequent alcohol drinking in male and less physical activity in female could explain the higher risk of CRC in this study.

There were several limitations to our study. First, the NHIS-Health Examination Cohort was established based on administrative data for health insurance claims instead of clinical data for disease progress. Therefore, we could not analyze the data according to CKD stage classified based on laboratory results. However, CKD was defined according to the same method used in previously published papers.[@B4][@B35][@B36][@B37][@B38] Second, study subjects were selected by matching age and sex, as susceptibility to chronic diseases increases with age. Nevertheless, due to a failure to take into account new cases of CKD or DM onset during the observation period, the association may be diluted in terms of misclassification bias. Third, this study was a retrospective design, and thus, selection bias could not be avoided completely. Fourth, we included all diabetic patients (type I and II DM) in this study. Most studies of the association between DM and CRC investigated patients with type II DM.[@B21][@B23][@B39] However, type II DM is significantly more prevalent than type I DM in Korea. The prevalence of type I DM is approximately 0.017%, whereas the prevalence of type II DM is 8.0% in Korea.[@B18][@B40] Finally, since this study included only Korean individuals, our findings should be interpreted with caution when attempting to apply them to other ethnicities.

In conclusion, both DM and CKD alone, as well as CKD plus DM, were independently associated with an increased incidence of CRC, compared with healthy controls. CRC incidence was significantly increased in female with both CKD and DM compared with those with CKD only or DM only; however, this phenomenon was not observed in male. Our results suggest a significant difference in the effect of CKD or DM on the risk of CRC according to sex. However, prospective studies including various ethnic populations are needed to verify our results.
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SUPPLEMENTARY MATERIALS
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###### SUPPLEMENTARY MATERIAL 1

###### Supplementary Fig. 1

Study flow diagram. NHIS, National Health Insurance Service; DM, diabetes mellitus; CKD, chronic kidney disease; BMI, body mass index.

###### SUPPLEMENTARY MATERIAL 2

###### Supplementary Fig. 2

Kaplan-Meier analysis of CRC incidence according to CKD or DM. Difference in the CRC incidence according to CKD (A) or DM (B) using the Kaplan-Meier method and log-rank test. The cumulative incidence of CRC was significantly increased in the CKD or DM group, compared with the control group (*p*\<0.0001). CRC, colorectal cancer; CKD, chronic kidney disease; DM, diabetes mellitus.

![Kaplan-Meier curves for CRC incidence according to the presence of CKD or DM in male (A) and female (B). The cumulative incidence of CRC was significantly increased in the CKD−/DM+, CKD+/DM−, and CKD+/DM+ groups, compared with the control groups, in both male and female. However, in male, no significant difference was observed in the cumulative incidence of CRC between the CKD+/DM+ and the CKD−/DM+ or CKD+/DM− groups (A). In contrast, the cumulative incidence of CRC was significantly increased in the CKD+/DM+ group, compared with the CKD−/DM+ or CKD+/DM− group, in female (B). CRC, colorectal cancer; CKD, chronic kidney disease; DM, diabetes mellitus.](ymj-61-506-g001){#F1}

![Differential impact of CKD, DM, or both on CRC incidence between male and female. The HR for CRC incidence was significantly higher in the CKD+/DM+ group, compared with the CKD−/DM+ or CKD+/DM− group, in the whole population (*p*=0.027 and *p*=0.025, respectively) and in female (*p*=0.007 and *p*=0.018, respectively) after adjusting for all possible variables (age, sex, income, BMI, smoker habit, alcohol consumption, exercise, CCI score, family history of cancer, metformin use, and aspirin or NSAID use). However, no statistical difference was observed in the cumulative incidence of CRC between the CKD+/DM+ group and CKD−/DM+ or CKD+/DM− group in male. CKD, chronic kidney disease; DM, diabetes mellitus; CRC, colorectal cancer; HR, hazard ratio.](ymj-61-506-g002){#F2}

###### Baseline Characteristics of the Study Groups Stratified according to the Presence of CKD or Diabetes

![](ymj-61-506-i001)

                                Control (n=97698)   Disease (n=48849)   Disease group                  
  ----------------------------- ------------------- ------------------- --------------- -------------- --------------
  Age (yr)                      57.9±9.7            57.9±9.7            58.1±9.4        57.3±10.0      58.8±9.2
  Male                          53,172 (54.4)       26586 (54.4)        9913 (56.0)     12031 (53.1)   4,642 (54.6)
  Income^\*^                                                                                           
   Medical-aid                  265 (0.3)           153 (0.3)           48 (0.3)        78 (0.3)       27 (0.3)
   1st--3rd                     23978 (24.5)        11605 (23.8)        4379 (24.7)     5390 (23.8)    1836 (21.6)
   4th--6th                     23127 (23.7)        11255 (23.0)        4237 (23.9)     5106 (22.6)    1912 (22.5)
   7th--8th                     19921 (20.4)        9931 (20.3)         3609 (20.4)     4531 (20.0)    1791 (21.1)
   9th--10th                    30407 (31.1)        15905 (32.6)        5427 (30.7)     7538 (33.3)    2940 (34.6)
  BMI (kg/m^2^)                                                                                        
   \<20                         8942 (9.2)          2342 (4.8)          708 (4.0)       1254 (5.5)     380 (4.5)
   20--24.9                     55400 (56.7)        24218 (49.6)        8863 (50.1)     11125 (49.1)   4230 (49.7)
   ≥25                          33356 (34.1)        22289 (45.6)        8129 (45.9)     10264 (45.3)   3896 (45.8)
  Smoking                                                                                              
   Non-smoker                   66974 (68.6)        33533 (68.6)        11955 (67.5)    15647 (69.1)   5931 (69.7)
   Ex-smoker                    8363 (8.6)          4422 (9.1)          1626 (9.2)      2048 (9.0)     748 (8.8)
   Current smoker               22361 (22.9)        10894 (22.3)        4119 (23.3)     4948 (21.9)    1827 (21.5)
  Drinking^†^                                                                                          
   No-drinking                  58294 (59.9)        30428 (62.6)        11095 (63.0)    13754 (60.9)   5579 (66.0)
   2--3 times/month             12927 (13.3)        6072 (12.5)         2032 (11.5)     3015 (13.4)    1025 (12.1)
   1--2 times/week              14102 (14.5)        6757 (13.9)         2495 (14.2)     3211 (14.2)    1051 (12.4)
   ≥3 times/week                11974 (12.3)        5374 (11.1)         1989 (11.3)     2587 (11.5)    798 (9.4)
  Exercise^‡^                                                                                          
   None                         58642 (60.9)        27054 (56.3)        9483 (54.4)     13146 (59.0)   4425 (52.8)
   1--2 times/week              19918 (20.7)        10345 (21.5)        3766 (21.6)     4735 (21.2)    1844 (22.0)
   ≥3 times/week                17728 (18.4)        10692 (22.2)        4181 (24.0)     4403 (19.8)    2108 (25.2)
  CCI score^§^                  0.5±0.8             0.8±1.0             0.7±0.9         0.8±1.1        0.9±1.1
  Family history of cancer^‖^   10322 (11.9)        4607 (10.6)         1558 (9.9)      2326 (11.6)    723 (9.6)
  Use of metformin              92 (0.1)            14687 (30.1)        9496 (53.6)     52 (0.2)       5139 (60.4)
  Use of aspirin or NSAIDs      65900 (67.5)        37413 (76.6)        13636 (77.0)    16934 (74.8)   6843 (80.4)

CKD, chronic kidney disease; DM, diabetes mellitus; BMI, body mass index; CCI, Charlson Comorbidity Index; NSAIDs, non-steroidal anti-inflammatory drugs.

Data are expressed as n (%).

^\*^Income level: the NHIS-health examination cohort provide income level data as medical aid beneficiaries, deciles for insured employees, and deciles for insured self-employed, ^†^Numbers vary due to missing data. (97297, 48631, 17611, 22567, and 8453 subjects for control, disease, CKD−/DM+, CKD+/DM−, and CKD+/DM+, respectively), ^‡^Numbers vary due to missing data. (96288, 48091, 17430, 22284, and 8377 subjects for control, disease, CKD−/DM+, CKD+/DM−, and CKD+/DM+, respectively), ^§^Depending on the study design, diabetes, complicated diabetes, cancer and metastatic cancer were not considered, ^∥^Numbers vary due to missing data (87032, 43382, 15753, 20121, and 7508 subjects for control, disease, CKD−/DM+, CKD+/DM−, and CKD+/DM+, respectively).

###### Incidence of Colorectal Cancer in the Study Groups according to the Presence of CKD or Diabetes

![](ymj-61-506-i002)

  Group       Total   Incident case   Incidence^\*^ (95% CI)   IRR (95% CI)
  ----------- ------- --------------- ------------------------ ----------------
  All                                                          
   Control    97698   1812            179.2 (170.9--187.4)     reference
   CKD-/DM+   17700   398             223.3 (201.3--245.2)     1.2 (1.1--1.4)
   CKD+/DM-   22643   549             234.3 (214.7--253.9)     1.3 (1.2--1.4)
   CKD+/DM+   8506    244             285.4 (249.6--321.2)     1.6 (1.4--1.8)
  Male                                                         
   Control    53172   1163            212.5 (200.3--224.7)     reference
   CKD-/DM+   9913    252             254.1 (222.7--285.5)     1.2 (1.0--1.4)
   CKD+/DM-   12031   344             277.4 (248.1--306.7)     1.3 (1.2--1.5)
   CKD+/DM+   4642    141             302.5 (252.6--352.4)     1.4 (1.2--1.7)
  Female                                                       
   Control    44526   649             139.8 (129.1--150.6)     reference
   CKD-/DM+   7787    146             184.6 (154.6--214.5)     1.3 (1.1--1.6)
   CKD+/DM-   10612   205             185.8 (160.4--211.2)     1.3 (1.1--1.6)
   CKD+/DM+   3864    103             264.8 (213.7--315.9)     1.9 (1.5--2.3)

CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; IRR, incidence rate ratio.

^\*^Incidence per 100000 person-years.

###### Cox Proportional Hazards Regression Analysis of the Cumulative Incidence of Colorectal Cancer

![](ymj-61-506-i003)

                                                          Unadjusted Cox regression analysis   Multivariate Cox regression analysis^\*^                       
  ------------------------------------------------------- ------------------------------------ ------------------------------------------ ------------------- ---------
  Group (vs. control)                                                                                                                                         
   CKD-/DM+                                               1.26 (1.13--1.40)                    \<0.001                                    1.34 (1.16--1.55)   \<0.001
   CKD+/DM-                                               1.31 (1.19--1.44)                    \<0.001                                    1.31 (1.18--1.46)   \<0.001
   CKD+/DM+                                               1.61 (1.41--1.84)                    \<0.001                                    1.63 (1.37--1.94)   \<0.001
  Age (per 1-year increase)                               1.06 (1.06--1.06)                    \<0.001                                    1.06 (1.06--1.07)   \<0.001
  Male (vs. female)                                       1.46 (1.36--1.57)                    \<0.001                                    1.55 (1.41--1.72)   \<0.001
  Income (continuous variable from Medical-aid to 10th)   0.97 (0.96--0.99)                    \<0.001                                    0.98 (0.97--1.00)   0.014
  BMI (vs. 20--25 kg/m^2^)                                                                                                                                    
   \<20                                                   1.35 (1.19--1.53)                    \<0.001                                    1.13 (0.98--1.29)   0.094
   ≥25                                                    0.96 (0.89--1.04)                    0.337                                      1.03 (0.94--1.11)   0.557
  Smoking (vs. non-smoker)                                                                                                                                    
   Ex-smoker                                              1.23 (1.09--1.39)                    \<0.001                                    1.05 (0.91--1.21)   0.499
   Current smoker                                         1.25 (1.15--1.36)                    \<0.001                                    1.17 (1.06--1.30)   0.003
  Drinking (vs. non-drinker)                                                                                                                                  
   2--3 times/month                                       1.00 (0.89--1.12)                    0.974                                      1.13 (0.99--1.28)   0.063
   1--2 times/week                                        1.05 (0.94--1.17)                    0.393                                      1.15 (1.01--1.30)   0.030
   ≥3 times/week                                          1.53 (1.38--1.69)                    \<0.001                                    1.36 (1.20--1.53)   \<0.001
  Exercise (vs. ≥3 times/week)                                                                                                                                
   None                                                   1.05 (0.95--1.15)                    0.346                                      1.03 (0.93--1.14)   0.584
   1--2 times/week                                        0.88 (0.78--0.99)                    0.031                                      0.99 (0.88--1.13)   0.925
  CCI score (per 1 unit increase)                         1.21 (1.16--1.25)                    \<0.001                                    1.09 (1.04--1.13)   \<0.001
  Family history of cancer (vs. no history)               0.84 (0.74--0.95)                    0.006                                      1.03 (0.90--1.17)   0.670
  Use of metformin (vs. non-use)                          1.19 (1.07--1.34)                    0.002                                      0.92 (0.78--1.08)   0.302
  Use of aspirin or NSAIDs (vs. non-use)                  1.13 (1.04--1.22)                    0.004                                      0.99 (0.90--1.08)   0.750

HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; BMI, body mass index; CCI, Charlson Comorbidity Index; NSAIDs, non-steroidal anti-inflammatory drugs.

^\*^Adjusted for presence of CKD or DM, age, sex, income, BMI, smoker habits, alcohol intake, exercise, CCI score, family history of cancer, metformin use, use of aspirin or NSAIDs.

###### Cox Proportional Hazards Regression Analysis of the Cumulative Incidence of Colorectal Cancer according to Sex
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                                                          Male                Female                                                                                    
  ------------------------------------------------------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- ---------
  Group (vs. control)                                                                                                                                                   
   CKD-/DM+                                               1.20 (1.05--1.38)   0.008     1.32 (1.11--1.59)   0.002     1.33 (1.11--1.59)   0.002     1.38 (1.08--1.75)   0.010
   CKD+/DM-                                               1.31 (1.16--1.47)   \<0.001   1.26 (1.11--1.44)   \<0.001   1.33 (1.14--1.56)   \<0.001   1.39 (1.18--1.65)   \<0.001
   CKD+/DM+                                               1.44 (1.21--1.71)   \<0.001   1.43 (1.14--1.79)   0.002     1.92 (1.56--2.36)   \<0.001   2.00 (1.52--2.63)   \<0.001
  Age (per 1-year increase)                               1.07 (1.06--1.07)   \<0.001   1.07 (1.06--1.07)   \<0.001   1.06 (1.05--1.07)   \<0.001   1.06 (1.05--1.07)   \<0.001
  Income (continuous variable from Medical-aid to 10th)   0.96 (0.95--0.97)   \<0.001   0.98 (0.97--1.00)   0.040     0.98 (0.96--1.00)   0.061     0.99 (0.97--1.01)   0.259
  BMI (vs. 20--25 kg/m^2^)                                                                                                                                              
   \<20                                                   1.41 (1.21--1.64)   \<0.001   1.15 (0.97--1.36)   0.103     1.24 (0.99--1.54)   0.061     1.07 (0.84--1.37)   0.581
   ≥25                                                    0.91 (0.82--1.00)   0.049     1.02 (0.92--1.13)   0.740     1.10 (0.97--1.24)   0.141     1.03 (0.91--1.18)   0.628
  Smoking (vs. non-smoker)                                                                                                                                              
   Ex-smoker                                              0.95 (0.83--1.09)   0.467     1.03 (0.89--1.19)   0.735     1.56 (0.95--2.55)   0.080     1.39 (0.81--2.36)   0.231
   Current smoker                                         0.96 (0.87--1.06)   0.386     1.16 (1.04--1.29)   0.010     1.74 (1.34--2.27)   \<0.001   1.39 (1.04--1.86)   0.028
  Drinking (vs. non-drinker)                                                                                                                                            
   2--3 times/month                                       0.83 (0.73--0.96)   0.010     1.09 (0.94--1.27)   0.254     0.99 (0.80--1.23)   0.952     1.23 (0.98--1.55)   0.079
   1--2 times/week                                        0.86 (0.76--0.97)   0.014     1.15 (1.01--1.32)   0.041     0.90 (0.64--1.24)   0.507     1.09 (0.76--1.56)   0.653
   ≥3 times/week                                          1.24 (1.11--1.39)   \<0.001   1.37 (1.20--1.55)   \<0.001   0.98 (0.61--1.59)   0.943     1.11 (0.67--1.83)   0.683
  Exercise (vs. ≥3 times/week)                                                                                                                                          
   None                                                   1.01 (0.90--1.13)   0.843     0.94 (0.83--1.06)   0.275     1.37 (1.15--1.63)   \<0.001   1.27 (1.05--1.54)   0.013
   1--2 times/week                                        0.79 (0.69--0.91)   \<0.001   0.97 (0.84--1.12)   0.660     1.06 (0.83--1.34)   0.651     1.07 (0.83--1.39)   0.596
  CCI score (per 1 unit increase)                         1.25 (1.20--1.31)   \<0.001   1.09 (1.03--1.15)   0.003     1.22 (1.15--1.28)   \<0.001   1.08 (1.01--1.15)   0.019
  Family history of cancer (vs. no history)               0.83 (0.71--0.98)   0.027     1.02 (0.87--1.21)   0.780     0.85 (0.69--1.04)   0.114     1.04 (0.84--1.28)   0.709
  Use of metformin (vs. non-use)                          1.16 (1.01--1.34)   0.040     0.92 (0.75--1.14)   0.442     1.26 (1.05--1.51)   0.013     0.91 (0.70--1.19)   0.478
  Use of aspirin or NSAIDs (vs. non-use)                  1.19 (1.08--1.31)   \<0.001   0.97 (0.87--1.08)   0.610     1.27 (1.09--1.48)   0.003     1.02 (0.86--1.21)   0.839

HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; BMI, body mass index; CCI, Charlson Comorbidity Index; NSAIDs, non-steroidal anti-inflammatory drugs.

^\*^Adjusted for presence of CKD or DM, age, sex, income, BMI, smoker habits, alcohol intake, exercise, CCI score, family history of cancer, metformin use, use of aspirin or NSAIDs.

[^1]: ^\*^Hyung Jung Oh and Hye Ah Lee contributed equally to this work.
